2. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 2000; 92(9): 709–20. doi: 10.1093/jnci/92.9.709

3. Pimenoff V.N., de Oliveira C.M., Bravo I.G. Transmission between Archaic and Modern Human Ancestors during the Evolution of the Oncogenic Human Papillomavirus 16. Mol. Biol. Evol. 2017; 34(1): 4–19. doi: 10.1093/molbev/msw214

4. De Villiers E.-M., Fauquet C., Broker T. R., Bernard H.-U., zur Hausen H. Classification of papillomaviruses. Virology 2004; 324(1): 17–27. doi: 10.1016/j.virol.2004.03.033

5. de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health. 2020; 8(2): e180–90. doi: 10.1016/S2214-109X(19)30488-7

6. Mena M., Frias-Gomez J., Taberna M., Quirós B., Marquez S., Clavero O. et al. Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe. Sci. Rep. 2020; 10(1): 13219. doi: 10.1038/s41598-020-70118-7

7. Белякова Е.Н., Брико Н.И., Лопухов П.Д. Характеристика заболеваемости раком головы и шеи, потенциально ассоциированным с вирусом папилломы человека, в России в 2007–2018 гг. Профилактическая медицина 2021; 24(2): 30–6. https://doi.org/ 10.17116/profmed20212402130

Belyakova E.N., Briko N.I., Lopukhov P.D. [Characteristics of the head and neck cancer incidence potentially associated with human papillomavirus in Russia in 2007–2018]. Preventive Medicine 2021; 24(2): 30–6. (In Russ.). https://doi.org/10.17116/profmed20212402130

8 Castellsagué X., Alemany L., Quer M. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J. Natl. Cancer Inst. 2016; 108(6): djv403. doi: 10.1093/jnci/djv403

9. Rettig E.M., Zaidi M., Faraji F., Eisele D.W., El Asmar M., Fung N., et al. Oropharyngeal cancer is no longer a disease of younger patients and the prognostic advantage of human papillomavirus is attenuated among older patients: Analysis of the national cancer database. Oral. Oncol. 2018; 83: 147–53. doi: 10.1016/j. oraloncology.2018.06.013

10. Chaturvedi A .K., Anderson W.F., Lortet-Tieulent J., Curado M.P., Ferlay J., Franceschi S. et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J. Clin. Oncol. 2013; 31: 4550–9. doi: 10.1200/JCO.2013.50.3870

11. WHO/IVB Database, as at June 2020 Map production: Countries with HPV vaccine in the national immunization programme. https://www.who.int/immunization/monito­ring_surveillance/VaccineIntroStatus.pptx

12. Grant A., Hansl B. Russia economic report: the dawn of a new economic era? Russia economic report. # 33. Washington, DC: World Bank Group, 2015.

13. Onerci Celebi O., Sener E., Hosal S., Cengiz M., Gullu I., & Guler Tezel G. Human papillomavirus infection in patients with laryngeal carcinoma. BMC Cancer 2018; 18(1). doi: 10.1186/s12885-018-4890-8

14. Anantharaman D., Abedi-Ardekani B., Beachler D.C., Gheit T., Olshan A. F., Wisniewski K. et al. Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. Int. J. Cancer 2017; 140(9): 1968–75. doi:10.1002/ijc.30608

15. Giuliano A.R., Nyitray A.G., Kreimer A.R., Pierce Campbell C.M., Goodman M.T., Sudenga S.L. et al. EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int. J. Cancer. 2015; 136: 2752–60. doi: 10.1002/ijc.29082

16. Ho G.Y., Studentsov Y., Hall C.B., Bierman R., Beardsley L., Lempa M., Burk R.D.: Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J. Infect. Dis. 2002; 186: 737–42. doi: 10.1086/342972

17. Kingma D.W., Allen R.A., Moore W., Caughron S.K., Melby M., Gillies E.M. et al. HPV genotype distribution in oral and oropharyngeal squamous cell carcinoma using seven in vitro amplification assays. Anticancer Res. 2010; 30(12): 5099–104.

18. Anil K., Chaturvedi E., Engels A., Hernandez B.Y., Xiao W., Kim E., et al. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. J. Clin. Oncol. 2011; 29(32): 4294–301. doi: 10.1200/JCO.2011.36.4596

19. Fakhry C., Westra W.H., Wang S.J., Zante A., Zhang Y., Rettig E. et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer 2017; 123(9): 1566–75. doi: 10.1002/cncr.30353

20. Meng H., Miao S., Chen K., Li H., Yao G., Geng J. et al. Association of p16 as Prognostic Factors for Oropharyngeal Cancer: Evaluation of p16 in 1470 Patients for a 16 Year Study in Northeast China. BioMed Res. Int. 2018: 1–8. doi: 10.1155/2018/9594568

21. Tsai S. C.-S., Huang J.-Y., Lin C., Liaw Y.P., Lin F.C. The association between human papillomavirus infection and head and neck cancer. Medicine (Baltimore). 2019; 98(7): e14436. doi: 10.1097/md. 0000000000014436

22. Fakhry C., Westra W. H., Li S., Cmelak A., Ridge J.A., Pinto H., et al. Improved Survival of Patients with Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial. JNCI 2008; 100(4): 261–9. doi: 10.1093/jnci/djn011